{
  "id": "61fbc3d5c9dfcb9c0900000e",
  "type": "list",
  "question": "Which drugs are included in the Qtern pill?",
  "ideal_answer": "Qtern pill includes saxagliptin and dapagliflozin. It is indicated in the EU for the improvement of glycaemic control in adults with type 2 diabetes mellitus.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29176433",
    "http://www.ncbi.nlm.nih.gov/pubmed/28176222",
    "http://www.ncbi.nlm.nih.gov/pubmed/28884600",
    "http://www.ncbi.nlm.nih.gov/pubmed/32454718"
  ],
  "snippets": [
    {
      "text": "Objectives: The fixed dose combination of saxagliptin and dapagliflozin is a recently approved antidiabetic medication. It is marketed under the brand name Qtern. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32454718",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of the fixed-dose combination (FDC) product, QTERN (dapagliflozin/saxagliptin) tablets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884600",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Saxagliptin/dapagliflozin fixed-dose combination tablets (Qtern\u00ae) are indicated in the EU for the improvement of glycaemic control in adults with type 2 diabetes mellitus (T2DM), either when treatment with metformin and/or a sulfonylurea plus a monocomponent of saxagliptin/dapagliflozin provides inadequate glycaemic control, or when the patient is already being treated with the free combination of saxagliptin\u00a0+\u00a0dapagliflozin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28176222",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article highlights the following new drugs: brodalumab (Siliq), dapagliflozin and saxagliptin (Qtern), dupilumab (Dupixent), oxymetazoline (Rhofade), safinamide (Xadago), and sarilumab (Kevzara).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29176433",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of the fixed-dose combination (FDC) product, QTERN (dapagliflozin/saxagliptin) table",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884600",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of the fixed-dose combination (FDC) product, QTERN (dapagliflozin/saxagliptin) tablet",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884600",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: QTERN (dapagliflozin/saxagliptin) tablets are a reasonable option for patients with T2DM not controlled on metformin, but cost, insurance coverage, and a lackluster reduction in A1C will likely limit its use until more data regarding its effects on complications of diabetes and cardiovascular outcomes become availabl",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884600",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article highlights the following new drugs: brodalumab (Siliq), dapagliflozin and saxagliptin (Qtern), dupilumab (Dupixent), oxymetazoline (Rhofade), safinamide (Xadago), and sarilumab (Kevzara)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29176433",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of the fixed-dose combination (FDC) product, QTERN (dapagliflozin/saxagliptin) tablets.DATA SOURCES: Searches of MEDLINE (1946 to July 1, 2017) were conducted using the keywords QTERN, saxagl",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884600",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nd dapagliflozin + metformin was -0.27 (95% CI = -0.48 to -0.05, P = 0.0166). The combination was well tolerated when added to metformin.CONCLUSION: QTERN (dapagliflozin/saxagliptin) tablets are a reasonable option for patients with T2DM not controlled on metformin, but cost, insurance coverage, and a lackluster reduction in A1C will likely limit its use until more data regard",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884600",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "saxagliptin, dapagliflozin"
}